君實生物(01877.HK)向集合管理計劃進行戰略配售
格隆匯5月27日丨君實生物(01877.HK)公佈,集團部分高級管理人員及核心員工設立集合管理計劃參與A股發售項下的戰略配售。因此,公司擬與集合管理計劃及中金公司(作為A股發售的保薦人及主承銷商)訂立戰略配售協議。
根據配售協議,戰略配售項下A股總認購金額將為人民幣2.59億元(包括經紀佣金及税項)。將向集合管理計劃發行的A股發行價將與A股發售下的A股發行價相同。將向集合管理計劃發行的實際A股數目將按A股最終發行價釐定。集合管理計劃將予認購的A股總數不得超過根據A股發售建議發行A股總數的10%。因此,根據戰略配售將予發行的最高A股數目為871.3萬股A股。集合管理計劃將予認購的A股總數不得超過根據A股發售建議發行A股總數的10%。
公告稱,設立集合管理計劃及戰略配售旨在挽留、動員及激勵公司員工,並使彼等的利益與股東利益保持一致。參與人為公司高級管理人員及核心員工,彼等各自均在集團的營運及管理中發揮重要作用。參與人亦涵蓋公司所有主要職能。公司認為,集合管理計劃將有利於挽留參與人,並激勵彼等改善公司的業績。公司亦相信,戰略配售將使公司的高級管理人員及核心員工能夠參與公司的股權架構,從而促進公司股權架構的多元化及提升企業管治。
公司從戰略配售獲得的募集資金將與A股發售募集資金的用途一致,即創新藥研發、臨港生產基地(本集團位於中國上海奉賢區臨港產業園的在建中生產基地)建設項目、償還銀行貸款及補充現金流量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.